Elicio Therapeutics (ELTX) Other Non-Current Liabilities (2022 - 2026)

Elicio Therapeutics (ELTX) has 5 years of Other Non-Current Liabilities data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 21.51% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 21.51% YoY), and the FY2025 full-year result was $2.6 million, down 7.53% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $3.6 million, up from $2.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $23.2 million in Q3 2024 and bottomed at $11000.0 in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $2.9 million (2024), against an average of $4.3 million.
• The widest annual swing landed in 2024, when Other Non-Current Liabilities soared 25609.09%; it then plunged 85.89% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $81000.0 in 2022, then sank by 86.42% to $11000.0 in 2023, then jumped by 25609.09% to $2.8 million in 2024, then declined by 7.53% to $2.6 million in 2025, then soared by 37.63% to $3.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.

Peer Comparison